Review: Inhaled anticholinergics increase risk of major cardiovascular events in COPD

Evidence-Based Medicine

Volumn 14, Issue 2, 2009, Pages 42-43

  Stanbrook, Matthew B ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; FLUTICASONE PROPIONATE PLUS SALMETEROL; PLACEBO; SALBUTAMOL; SALMETEROL; TIOTROPIUM BROMIDE;

CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; NOTE; SIDE EFFECT; STROKE; SUDDEN DEATH; TREATMENT OUTCOME;

EID: 64849117859     PISSN: 13565524     EISSN: 14736810     Source Type: Journal    
DOI: 10.1136/ebm.14.2.42     Document Type: Note

References (3)

1. Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007;146:545-55.
2. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of COPD. November 2008. www.goldcopd.org (accessed 9 Dec 2008).
3. O'Donnell DE, Aaron S, Bourbeau J, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease-2007 update. Can Respir J 2007;14:5B-32B. Tiotropium reduced exacerbations but not rate of FEV1 decline in patients with COPD using other respiratory medications